<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02923700</url>
  </required_header>
  <id_info>
    <org_study_id>PRP014</org_study_id>
    <nct_id>NCT02923700</nct_id>
  </id_info>
  <brief_title>Leukocyte-rich PRP vs Leukocyte-poor PRP for the Treatment of Knee Cartilage Degeneration: a Randomized Controlled Trial</brief_title>
  <acronym>PRP014</acronym>
  <official_title>Leukocyte-rich PRP vs Leukocyte-poor PRP for the Treatment of Knee Cartilage Degeneration: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Ortopedico Rizzoli</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituto Ortopedico Rizzoli</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Platelet-rich Plasma (PRP) is the most exploited biologic agents currently used for the
      treatment of osteoarthritis (OA) of different joints, in particular knee OA.

      In previous studies, it has been showed its potential to reduce pain and improve functional
      status in patients treated by simple intra-articular injections. However, there are several
      PRP formulation currently available in clinical use, and therefore it is very difficult to
      compare data coming from trials using different products. The most debated aspect concerning
      PRP formulation is the role of leukocytes, which might stimulate an early inflammatory
      response in the joint due to the release of metalloproteases and other pro-inflammatory
      cytokines.

      The investigators hypothesized that the presence of leukocytes in PRP could be clinically
      relevant in terms of outcome, so the present double blind randomized controlled trial was
      designed to compare leukocyte-rich and leukocyte-poor PRP injections for the treatment of
      knee OA.

      A power analysis has been performed for the primary endpoint of IKDC (International Knee
      Documentation Committee) subjective score improvement at the 12-month follow-up for PRP. From
      a pilot study, a standard deviation of 15.2 points was found. With an alpha error of 0.05, a
      beta error of 0.2 and a minimal clinically significant difference of 6.7 points corresponding
      at 1/3 of the documented mean improvement, the minimum sample size was 83 for each group.
      Considering a possible drop out of 15%, 96 patients per group are required for total 192
      patients, selected according to well-defined inclusion criteria (see 'Eligibility criteria'
      section). Patients are then assigned to two different treatment groups, according to a
      randomization list. The first group of treatment consists of three weekly intra-articular
      injections of autologous leukocyte-rich PRP, whereas the second group of patients will be
      treated by three intra-articular injections of leukocyte-poor PRP.

      PRP will be obtained with the following procedure: a 300-ml autologous venous blood sample
      will undergo 2 centrifugations (the first at 1480 rpm for 6 minutes to separate erythrocytes,
      and a second at 3400 rpm for 15 minutes to concentrate platelets) to produced 20 ml of
      leukocyte-rich PRP. In case of patients allocated to receive leukocyte-poor PRP, a special
      filter will be then used to separate leukocytes and obtain leukocyte-poor PRP.

      The total amount of PRP will be divided into 4 small units of 5 ml each. One unit is sent to
      the laboratory for analysis of platelet concentration and for a quality test, 3 units are
      stored at -30° C.

      One week after the PRP production, the injective treatment starts, with 3 weekly injections.
      At the moment of the injection the syringe is properly covered to prevent the patient from
      discovering the substance he was receiving. After the injection, patients are sent home with
      instructions to limit the use of the leg for at least 24 h and to use cold therapy/ice on the
      affected area to relieve pain. During this period, the use of non-steroidal medication is
      forbidden.

      Patients are prospectively evaluated basally and at 2, 6, and 12 months of follow-up using
      clinical subjective scores and objective parameters to determine clinical outcome (see
      'Outcome measure' section). Patient satisfaction and adverse events will be also reported.
      All the clinical evaluations are performed by a medical staff not involved in the injective
      procedure, in order to keep the study double blinded. At the end of the study, the nature of
      the injected substance is revealed to the patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>IKDC (International knee documentation committee) score trend over time</measure>
    <time_frame>basal (i.e. pre-treatment), 1 month, 2 months, 6 months and 12 months after treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>KOOS (Knee Outcome Osteoarthritis Score) trend over time</measure>
    <time_frame>basal (i.e. pre-treatment), 1 month, 2 months, 6 months and 12 months after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAS (Visual Analogue Scale) for Pain trend over time</measure>
    <time_frame>basal (i.e. pre-treatment), 1 month, 2 months, 6 months and 12 months after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tegner Score trend over time</measure>
    <time_frame>basal (i.e. pre-treatment), 1 month, 2 months, 6 months and 12 months after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events report during follow-up period</measure>
    <time_frame>ba1 month, 2 months, 6 months and 12 months after treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">192</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Leukocyte-rich PRP group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three weekly knee intra-articular injections of leukocyte-rich PRP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Leukocyte-poor PRP group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three weekly knee intra-articular injections of leukocyte-poor PRP</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Leukocyte-rich PRP intra-articular injections</intervention_name>
    <arm_group_label>Leukocyte-rich PRP group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Leukocyte-poor PRP intra-articular injections</intervention_name>
    <arm_group_label>Leukocyte-poor PRP group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. patients affected by mono-lateral symptomatic knee articular degenerative pathology
             with history of chronic (for at least 4 months) pain or swelling;

          2. imaging findings of degenerative changes of the joint (osteoarthritis or chondropathy
             with Kellgren Lawrence Score from 0 to 3 at X-ray evaluation).

        Exclusion Criteria:

          -  age &gt; 80 years;

          -  Kellgren-Lawrence score at X-ray evaluation &gt; 3;

          -  major axial deviation (varus &gt;5° , valgus &gt; 5°),

          -  systemic disorders such as diabetes, rheumatoid arthritis, haematological diseases
             (coagulopathy), severe cardiovascular diseases, infections, immunodepression;

          -  patients in therapy with anticoagulants or antiaggregants;

          -  use of NSAIDs in the 5 days before blood donation;

          -  patients with Hb values &lt; 11 g/dl and platelet values &lt; 150,000/mmc.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Berardo Di Matteo, MD</last_name>
    <role>Study Chair</role>
    <affiliation>I Clinic, Rizzoli Orthopaedic Institute, Bologna, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alessandro Di Martino, MD</last_name>
    <role>Study Chair</role>
    <affiliation>I Clinic, Rizzoli Orthopaedic Institute, Bologna, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francesco Tentoni, MD</last_name>
    <role>Study Chair</role>
    <affiliation>I Clinic, Rizzoli Orthopaedic Institute, Bologna, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alice Roffi, BA</last_name>
    <role>Study Chair</role>
    <affiliation>Rizzoli Orthopaedic Institute, Bologna, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elizaveta Kon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>I Clinic, Rizzoli Orthopaedic Institute, Bologna, Italy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elizaveta Kon, MD</last_name>
    <phone>+39 0516366567</phone>
    <email>e.kon@biomec.ior.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Giuseppe Filardo, MD</last_name>
    <phone>+39 0516366567</phone>
    <email>g.filardo@ior.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rizzoli Orthopaedic Institute</name>
      <address>
        <city>Bologna</city>
        <state>Emilia Romagna</state>
        <zip>40136</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizaveta Kon, MD</last_name>
      <phone>+39 0516366567</phone>
      <email>e.kon@biomec.ior.it</email>
    </contact>
    <contact_backup>
      <last_name>Giuseppe Filardo, MD</last_name>
      <phone>+39 0516366567</phone>
      <email>g.filardo@ior.it</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Di Matteo B, Loibl M, Andriolo L, Filardo G, Zellner J, Koch M, Angele P. Biologic agents for anterior cruciate ligament healing: A systematic review. World J Orthop. 2016 Sep 18;7(9):592-603. doi: 10.5312/wjo.v7.i9.592. eCollection 2016 Sep 18.</citation>
    <PMID>27672573</PMID>
  </reference>
  <reference>
    <citation>van Drumpt RA, van der Weegen W, King W, Toler K, Macenski MM. Safety and Treatment Effectiveness of a Single Autologous Protein Solution Injection in Patients with Knee Osteoarthritis. Biores Open Access. 2016 Aug 1;5(1):261-8. doi: 10.1089/biores.2016.0014. eCollection 2016.</citation>
    <PMID>27668131</PMID>
  </reference>
  <reference>
    <citation>Mlynarek RA, Kuhn AW, Bedi A. Platelet-Rich Plasma (PRP) in Orthopedic Sports Medicine. Am J Orthop (Belle Mead NJ). 2016 Jul-Aug;45(5):290-326. Review.</citation>
    <PMID>27552452</PMID>
  </reference>
  <reference>
    <citation>Sánchez M, Delgado D, Sánchez P, Muiños-López E, Paiva B, Granero-Moltó F, Prósper F, Pompei O, Pérez JC, Azofra J, Padilla S, Fiz N. Combination of Intra-Articular and Intraosseous Injections of Platelet Rich Plasma for Severe Knee Osteoarthritis: A Pilot Study. Biomed Res Int. 2016;2016:4868613. doi: 10.1155/2016/4868613. Epub 2016 Jul 4.</citation>
    <PMID>27462609</PMID>
  </reference>
  <reference>
    <citation>Mariani E, Canella V, Cattini L, Kon E, Marcacci M, Di Matteo B, Pulsatelli L, Filardo G. Leukocyte-Rich Platelet-Rich Plasma Injections Do Not Up-Modulate Intra-Articular Pro-Inflammatory Cytokines in the Osteoarthritic Knee. PLoS One. 2016 Jun 3;11(6):e0156137. doi: 10.1371/journal.pone.0156137. eCollection 2016.</citation>
    <PMID>27258008</PMID>
  </reference>
  <reference>
    <citation>Sadabad HN, Behzadifar M, Arasteh F, Behzadifar M, Dehghan HR. Efficacy of Platelet-Rich Plasma versus Hyaluronic Acid for treatment of Knee Osteoarthritis: A systematic review and meta-analysis. Electron Physician. 2016 Mar 25;8(3):2115-22. doi: 10.19082/2115. eCollection 2016 Mar.</citation>
    <PMID>27123220</PMID>
  </reference>
  <reference>
    <citation>Yang J, Lu Y, Guo A. Platelet-rich plasma protects rat chondrocytes from interleukin-1β-induced apoptosis. Mol Med Rep. 2016 Nov;14(5):4075-4082. doi: 10.3892/mmr.2016.5767. Epub 2016 Sep 23.</citation>
    <PMID>27665780</PMID>
  </reference>
  <reference>
    <citation>Yin WJ, Xu HT, Sheng JG, An ZQ, Guo SC, Xie XT, Zhang CQ. Advantages of Pure Platelet-Rich Plasma Compared with Leukocyte- and Platelet-Rich Plasma in Treating Rabbit Knee Osteoarthritis. Med Sci Monit. 2016 Apr 17;22:1280-90.</citation>
    <PMID>27086145</PMID>
  </reference>
  <reference>
    <citation>Smyth NA, Haleem AM, Ross KA, Hannon CP, Murawski CD, Do HT, Kennedy JG. Platelet-Rich Plasma May Improve Osteochondral Donor Site Healing in a Rabbit Model. Cartilage. 2016 Jan;7(1):104-11. doi: 10.1177/1947603515599190.</citation>
    <PMID>26958322</PMID>
  </reference>
  <reference>
    <citation>Smith PA. Intra-articular Autologous Conditioned Plasma Injections Provide Safe and Efficacious Treatment for Knee Osteoarthritis: An FDA-Sanctioned, Randomized, Double-blind, Placebo-controlled Clinical Trial. Am J Sports Med. 2016 Apr;44(4):884-91. doi: 10.1177/0363546515624678. Epub 2016 Feb 1.</citation>
    <PMID>26831629</PMID>
  </reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 30, 2016</study_first_submitted>
  <study_first_submitted_qc>September 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 4, 2016</study_first_posted>
  <last_update_submitted>September 12, 2017</last_update_submitted>
  <last_update_submitted_qc>September 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Istituto Ortopedico Rizzoli</investigator_affiliation>
    <investigator_full_name>Federica Balboni</investigator_full_name>
    <investigator_title>BScD</investigator_title>
  </responsible_party>
  <keyword>platelet rich plasma</keyword>
  <keyword>intra-articular injection</keyword>
  <keyword>leukocytes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

